Comparing Capecitabine vs Xeloda
Capecitabine | Xeloda |
|
---|
Capecitabine | Xeloda capecitabine |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescribed for Colorectal Cancer, Breast Cancer - Metastatic, Breast Cancer, Anal Cancer. May also be prescribed off label for Non-Small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Renal... View more |
Prescribed for Colorectal Cancer, Breast Cancer - Metastatic, Breast Cancer. Xeloda may also be used for purposes not listed in this medication guide. |
Choose a suggestion below Breast Cancer
Colorectal Cancer
Popular Comparisons
|
|||||||||||||||
More about Capecitabine | More about Xeloda (capecitabine) | ||||||||||||||||
Generic Status | |||||||||||||||||
Availability | |||||||||||||||||
Prescription only |
Prescription only |
||||||||||||||||
Ratings & Reviews | |||||||||||||||||
Capecitabine has an average rating of 6.4 out of 10 from a total of 44 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 30% reported a negative effect. |
Xeloda has an average rating of 6.9 out of 10 from a total of 25 ratings on Drugs.com. 62% of reviewers reported a positive effect, while 27% reported a negative effect. |
||||||||||||||||
Drug Class | |||||||||||||||||
Side Effects | |||||||||||||||||
Commonly reported side effects include: anemia, diarrhea, hyperbilirubinemia, increased serum alkaline phosphatase, increased serum transaminases, nausea, neutropenia, palmar-plantar erythrodysesthesia, paresthesia, stomatitis, thrombocytopenia, and vomiting. See the full capecitabine side effects document. |
Common side effects include: anemia, diarrhea, hyperbilirubinemia, increased serum alkaline phosphatase, increased serum transaminases, nausea, neutropenia, palmar-plantar erythrodysesthesia, paresthesia, stomatitis, thrombocytopenia, and vomiting. See the full Xeloda side effects document. |
||||||||||||||||
Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all capecitabine prices |
View all Xeloda prices and generic prices |
||||||||||||||||
Dosage Form(s) Available | |||||||||||||||||
|
|
||||||||||||||||
Brand Names | |||||||||||||||||
Xeloda |
N/A |
||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | |||||||||||||||||
0.75 hours |
0.75 hours |
||||||||||||||||
CSA Schedule** View glossary of terms | |||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | |||||||||||||||||
Category D
Positive evidence of risk
See the full Pregnancy Warnings document. |
Category D
Positive evidence of risk
See the full Pregnancy Warnings document. |
||||||||||||||||
Drug Interactions | |||||||||||||||||
A total of 231 drugs are known to interact with capecitabine:
|
A total of 231 drugs are known to interact with Xeloda:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
Disease Interactions | |||||||||||||||||
First Approval Date | |||||||||||||||||
April 30, 1998 |
April 30, 1998 |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | |||||||||||||||||
N/A |
N/A |
||||||||||||||||
More Information | |||||||||||||||||
Patient resources | |||||||||||||||||
Professional Resources | |||||||||||||||||
Related Treatment Guide | |||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.